- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$982.25 MnMarket Estimate, 2026
$1,057 MnMarket Forecast, 2034
$1,893 MnCAGR, 2026–2034
7.56%Executive Summary: Global Newborn Screening Market
- Market Scope:Global analysis of the newborn screening market, detailing testing technologies, dried blood spot methods, diagnostic instruments, and regional regulatory frameworks.
- Market Valuation:Valued at USD 982.25 million in 2025, reaching USD 1,057 million in 2026, and projected to expand to USD 1,893 million by 2034, growing at a robust CAGR of 7.56% from 2026 to 2034.
- Primary Growth Drivers:Rising prevalence of congenital and metabolic disorders, expanding government-mandated screening programs, and technological breakthroughs like tandem mass spectrometry.
Key Market Segment Metrics
| Category | Leading Segment (Base Position) | Fastest-Growing / High-Growth Segment |
|---|---|---|
| By Product | Consumables (ruling with a 65% market share through cost-effective dried blood cards, lancets, and routine collection kits) | Instruments (high-growth segment holding 35% share driven by automated diagnostic tools and advanced assay equipment) |
| By Test Type | Dried Blood Spot (dominant market share at 80% due to non-invasive application and efficiency in detecting metabolic disorders) | Hearing Screening (high-growth segment holding 15% share utilizing Otoacoustic Emission tests for early sensory deficit detection) |
| By Technology | Tandem Mass Spectrometry (leading with 45% share for precise, automated, and cost-effective detection of rare metabolic anomalies) | Enzyme Assay (high-growth segment accounting for 35% share favored for affordability and deployment in compact laboratories) |
| By Region | North America (regional leader with 40% share backed by well-established healthcare infrastructure and mandatory screening policies) | Asia-Pacific (lucrative high-growth region holding 20% share propelled by heavy birth volumes and CCHD pulse oximetry adoption) |
Major Market Players & Industry Landscape
Market Structure:Competitive diagnostic landscape featuring global medical technology leaders advancing genetic assays, mass spectrometry, and early-detection kits.
Key Companies:Agilent Technologies Inc., Natus Medical Incorporated, Bio-Rad Laboratories Inc., PerkinElmer, Inc., and Trivitron Healthcare.
Download Free Sample Report
Global Newborn Screening Market Size
The global newborn screening market was valued at USD 982.25 million in 2025, is estimated to reach USD 1,057 million in 2026, and is projected to reach USD 1,893 million by 2034, growing at a CAGR of 7.56% from 2026 to 2034.
MARKET DRIVERS
The rise in the number of newborn diseases is the biggest driver for the newborn screening market as the number of newborn babies diagnosed with hormonal, metabolic, and hearing disorders is increasing day by day.
As per the report by US CDC, 34 in every 10,000 births are diagnosed with newborn disorders. Amongst these, hearing loss is the most common disorder identified in the US. According to the Indian Pediatric Academy, congenital heart diseases are a more common newborn disorder in India with the prevalence of 9 in every 1000 births in the country.
The government of many nations has mandated newborn screening and also provides reimbursements and cost-effective screening in many regions.
This has helped to raise awareness regarding the newborn screening market and also, its adoption in many unpenetrated regions. Nowadays new screening technologies like tandem mass spectrometry have revolutionized the newborn screening market as the screening of a wider range of disorders with greater accuracy is now possible.
The increasing prevalence of newborn metabolic disorders in countries like the US and congenital heart diseases in newborns in India is driving the newborn screening market share.
Therefore, it can be concluded that a rise in the number of newborn diseases, government schemes and policies, and the development of new technologies in the newborn screening market are the major factors that drive the growth of the newborn screening market.
MARKET RESTRAINS
There is a lack of uniformity in the procedures followed in the newborn screening market across the world. This results in confusion in comparison of reports from different countries and thus might delay the diagnosis.
The cost of newborn screening is too high in some regions, which restricts people from opting the newborn screening tests. In developing countries, although reimbursement policies are being made by the government the poor healthcare system limits the growth of newborn screening market share. Human error can also affect the newborn screening market share growth as false negative reports can lead to late diagnosis and treatment of the newborn disease and the false positive report can lead to unnecessary anxiety financially as well as the stress on the health of the newborn will also be increased. Lack of awareness regarding the newborn screening market and the benefits associated with newborn screening also limits the reach of the newborn screening market in some of the unpenetrated markets as parents do not consider newborn screening.
Hence, lack of uniformity in the procedure, the high cost of carrying out the screening, human error, and lack of awareness are the major factors that limit the growth of the newborn screening market share.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Product, Test Type, Technology, and Region. |
| Various Analyses Covered | Global, Regional, and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Market Leaders Profiled | Agilent Technologies Inc., Natus Medical Incorporated,Bio-Rad Laboratories Inc., PerkinElmer, Inc., Trivitron Healthcare, Demant A/S, Covidien Plc. |
SEGMENTAL ANALYSIS
By Product Insights
The consumables segment is ruling the newborn screening market with a 65% market share. Consumables like dried blood cards (DBS), lancets and collection kits are more commonly used as they are cost-effective. Though these products are essential for the newborn screening process, these products do not provide accurate results in some cases.
The instruments segment accounts for 35% of the newborn screening market share. Technologically advanced methods like tandem mass spectrometry, various kinds of assays, and heart and hearing screening are included in this segment. As these methods are more accurate and efficient, this segment is also experiencing rapid growth in recent times.
By Test Type Insights
The Dried Blood Spot (DBS) type of test is ruling the newborn screening market with a market share of 80%. The dried blood spot method is a non-invasive test that is used for screening for conditions including hearing loss, genetic diseases, and metabolic disorders as well. Due to its efficiency and easy-handling nature, DBS is the most used method across the world.
The hearing screening test stands second in the newborn screening market with around 15% of the total market share. The test that is mostly used for hearing screening is the Otoacoustic Emission (OAE) test. It is used to test the response of the inner ear to sound.
The (CCHD) Congenital Heart Defects segment accounts for 5% of the newborn screening market share. A pulse oximetry test is carried out to diagnose any kind of defects in the heart. The blood oxygen level is tested in this method.
By Technology Insights
The tandem mass spectrometry is leading the newborn screening market with a 45% market share. Rare genetic disorders and other metabolic diseases can be easily diagnosed using this method. The process of tandem mass spectrometry can also be automated which makes a cost-effective method in the longer run.
The enzyme assay segment accounts for 35% of the newborn screening market share. Enzyme assay is an inexpensive and easy-to-perform method that makes it possible to be carried out in small labs as well.
The immunoassay method accounts for 15% of the newborn screening market share and is used for screening conditions like sickle cell disease and congenital hypothyroidism.
Pulse oximetry holds the lowest market share in the newborn screening market with only a 5% market share. Pulse oximetry is used for screening heart diseases by measuring the oxygen levels in the blood.
REGIONAL ANALYSIS
North America is leading the newborn screening market with a 40% market share. Well-established newborn screening infrastructure and properly planned policies and programs in the region drive the region towards growth in the newborn screening market. Also, the well-developed healthcare sector and easy availability of advanced technologies are prominent reasons for the rapid growth.
Europe stands second in the newborn screening market with a 30% market share. Strict government policies and cost reimbursement schemes in most European countries are the major factors for the growth of the newborn screening market in the region.
Asia Pacific region accounts for around 20% of the newborn screening market share. India is the biggest market for screening of CCHD and pulse oximetry method is the most used test in the country.
Latin America and Middle East & Africa hold the lowest market share in the newborn screening market.
KEY MARKET PLAYERS
Some of the companies that are playing a dominating role in the global newborn screening market include
- Agilent Technologies Inc.
- Natus Medical Incorporated
- Bio-Rad Laboratories Inc.
- PerkinElmer, Inc.
- Trivitron Healthcare
- Demant A/S
- Covidien Plc
GLOBAL NEWBORN SCREENING MARKET NEWS
- In September 2020, PerkinElmer received CE-IVD approval for the EONIS screening assay used to screen for SMA (spinal muscular atrophy), SCID (Severe Combined Immunodeficiency), and XLA (X- Linked Agammaglobulinemia) in newborns.
- In December 2019, PerkinElmer received US FDA approval for the GSP Neonatal Creatine Kinase MM (CK-MM) kit for screening newborns affected by Duchenne muscular dystrophy (DMD).
- In October 2019, in Germany, Demant A/S launched its easyScreen BERAphone, a hearing screening device.
MARKET SEGMENTATION
This global newborn screening market research report is segmented and sub-segmented into the following categories.
By Product
- Instrument
- Consumables
By Test Type
- Dried blood spot
- Hearing screening
- CCHD
By Technology
- Tandem mass spectrometry
- Enzyme assay
- Immunoassay
- Pulse oximetry
By Region
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa